Utilizing a CDST for Resistant/Refractory CMV in Hematopoietic Cell Transplant Patients

Program Overview

Join Drs. Kotton, Chemaly, and Papanicolaou as they illustrate how to use a new clinical decision support tool (CDST) for resistant or refractory cytomegalovirus (CMV) infection in hematopoietic cell transplant (HCT) patients. They will walk you through a challenging CMV resistant patient case and demonstrate how to enter clinical data into the novel CDST for optimal treatment decision making. Expert panel discussions provide an opportunity for you to learn how to apply the CDST in practice and incorporate a new therapy, maribavir, into the care of HCT patients with resistant or refractory CMV infection.

Credit Expired
0.5 CE Credit(s)
Expires: November 30, 2023

Target Audience

Transplantation, infectious disease, and oncology clinicians who manage patients with CMV infection after hematopoietic cell transplant.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Employ clinical decision support tool recommendations and current guidelines for the treatment of refractory cytomegalovirus (CMV) infection after transplantation
  • Identify risk factors for the development of refractory and drug resistant CMV after transplantation
  • Select treatment for refractory and drug resistant CMV after transplantation based on key data for recently approved therapies
  • Manage potential adverse effects associated with antiviral therapies for CMV

Activity Faculty

Camille Kotton portrait 2021

Camille Nelson Kotton, MD, FIDSA, FAST

Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, MA

Chemaly 500x500

Roy F. Chemaly, MD, MPH, FACP, FIDSA, CMQ

Professor, Medicine
Department of ID/IC/EH
Chief Infection Control Officer
Director, Clinical Virology Research Program
UT MD Anderson Cancer Center
Houston, TX

Genovefa Papanicolaou, MD

Genovefa Papanicolaou, MD

Infectious Disease Service
Memorial Sloan Kettering Cancer Center
Professor, Medicine
Weill Cornell Medical College, Cornell University
New York, NY

Supporter Statement

This activity is supported by an educational grant from Takeda.

Provider Statement

Provided by RMEI Medical Education, LLC.

Disclosure of Financial Relationships


Planners and Managers

Disclosure of Financial Relationships 

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. 


Camille Nelson Kotton, MD, FIDSA, FAST, has relevant financial relationships with Biotest, Evrys, Exevir, Hookipa, Merck, Oxford Immunotec, QIAGEN, Roche Diagnostics, Takeda (Consultant).

Roy Chemaly, MD, MPH, FACP, FIDSA, CMQ, has relevant financial relationships with AiCuris, Karius, Merck, Pulmotect, Inc. (Advisor); Ansun Biopharma, Janssen Pharmaceuticals, Oxford Immunotec, Shionogi Inc., Takeda, Xenex (Consultant); Ansun Biopharma, Eurofins-Viracor, Genentech, Karius, Merck, Oxford Immunotec, Takeda (Grant/Research Support).

Genovefa Papanicolaou, MD, has relevant financial relationships with AlloVir, MSD, Takeda (Consultant); MSD (Independent Contractor; including contracted research).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies. 

Planners and Managers

RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement 

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Credit Designation

Physician Continuing Medical Education 
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation 

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at [email protected]. 

Users must: 

  • Read the learning objectives and faculty disclosures 
  • Participate in the activity 
  • Complete the activity evaluation and attest to credit

There is no fee to participate. 



*The expense for this gift card is solely funded by RMEI Medical Education, LLC. 
No supporter funding was used for the expense of this gift card. 

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.   

Method of Participation and Request for Credit

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

© Copyright 2024. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | www.RMEI.com | (866) 770-RMEI


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources